John Martin Docherty net worth and biography

John Docherty Biography and Net Worth

Insider of Lexaria Bioscience

John became President of Lexaria in the Spring of 2015 and joined its board of directors a year later. Mr. Docherty was former President and Chief Operating officer of Helix BioPharma Corp. (TSX: HBP), where he led the company’s pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates.

Mr. Docherty is a senior operations and management executive with over 20 years of experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies, as well as emerging private and publicly-traded start-ups. At Helix, Mr. Docherty was also instrumental in the areas of investor and stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations, and he also served as a management member of its board of directors. Prior to this, Mr. Docherty was president and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for use with a range of active compounds.

Mr. Docherty has also held positions with companies such as Astra Pharma Inc., Nu-Pharm Inc. and PriceWaterhouseCoopers’ former global pharmaceutical industry consulting practice. He is a named inventor on issued and pending patents and he has a M.Sc. in Pharmacology and a B.Sc. in Toxicology from the University of Toronto.

What is John Martin Docherty's net worth?: The estimated net worth of John Martin Docherty is at least $1.24 thousand as of July 29th, 2025. Mr. Docherty owns 358 shares of Lexaria Bioscience stock worth more than $1,239 as of October 8th. This net worth estimate does not reflect any other investments that Mr. Docherty may own. Learn More about John Martin Docherty's net worth.
How do I contact John Martin Docherty?: The corporate mailing address for Mr. Docherty and other Lexaria Bioscience executives is 100 – 740 McCurdy Road, Kelowna, BC, V1X 2P7. Lexaria Bioscience can also be reached via phone at (250) 765-6424 and via email at [email protected]. Learn More on John Martin Docherty's contact information.
Has John Martin Docherty been buying or selling shares of Lexaria Bioscience?: John Martin Docherty has not been actively trading shares of Lexaria Bioscience within the last three months. Most recently, on Tuesday, July 29th, John Martin Docherty bought 358 shares of Lexaria Bioscience stock. The stock was acquired at an average cost of $13.95 per share, with a total value of $4,994.10. Following the completion of the transaction, the insider now directly owns 358 shares of the company's stock, valued at $4,994.10. Learn More on John Martin Docherty's trading history.
Who are Lexaria Bioscience's active insiders?: Lexaria Bioscience's insider roster includes Christopher Bunka (Director), and John Docherty (Insider). Learn More on Lexaria Bioscience's active insiders.

John Martin Docherty Insider Trading History at Lexaria Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/29/2025	Buy	358	$13.95	$4,994.10	358

John Martin Docherty Buying and Selling Activity at Lexaria Bioscience

Lexaria Bioscience Company Overview

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Today's Range

Now: $3.37

$3.32

$3.67

50 Day Range

MA: $6.86

$2.77

$14.15

2 Week Range

Now: $3.37

$2.77

$21.60

Volume

10,378 shs

Average Volume

27,782 shs

Market Capitalization

$7.10 million

P/E Ratio

N/A

Dividend Yield